1月12日，国家医保局公布一起医生受贿案详情。2025年4月，黑龙江省铁力市人民法院依法公开审理了 党某海犯非国家工作人员受贿罪一案。公诉机关指控，2012年至2023年期间，被告人党某海在担任双丰 林业局职工医院内科医生期间，利用开具处方的职务便利，收受多家医药公司业务员和销售经理给予的 药品回扣款，共计人民币789,110元。具体事实如下： 1. 2012年至2021年期间，被告人接受黑龙江省天一康阜医药有限公司业务员颜某民的请托，为该公司在 提高销售药品数量上提供帮助，颜某民在铁力市附近多次给予党某海药品回扣款共计48万元。 2. 2017年至2022年期间，被告人接受黑龙江省九昱医药有限责任公司销售经理孟某瑞的请托，为该公司 在提高销售药品数量上提供帮助，孟某瑞多次以微信转账、现金、银行转账等方式给予党某海药品回扣 款共计12.4万元。 医药商业贿赂本质上是通过给予不正当利益影响处方权，干扰正常诊疗行为，妨碍公平竞争，加重医药 负担。该案件中，受贿人作为临床一线医务人员，其开具处方并非从实际临床价值和产品质量疗效出 发，而是利用高返点和高回扣从中谋取私利。同时，受贿人接受的不正当利益均来自于经营流通企 ...

医药商业贿赂本质上是通过给予不正当利益影响处方权，干扰正常诊疗行为，妨碍公平竞争，加重医药 负担，使得医药产品销售从实际临床价值和产品的竞争力转为以高返点和高回扣驱动的不当竞争。司法 机关已经对行贿案件作出处罚，但案件暴露出的部分药品价格虚高空间依旧存在，虚高部分没有形成企 业正当盈利，也没有用于创新和质量，而是妨碍公平竞争。如不加以处置，虚高价格将持续侵害患者和 医保基金合法权益，也使合规经营企业受到错误示范。国家医保局于2020年建立价格招采信用评价制 度，对法院判决、有关部门查处的医药购销行贿、带金销售等问题突出的企业开展失信评级，并采取限 制挂网、配送等约束措施，使通过不当手段获取竞争优势的企业受相应约束，使合规经营企业感受公平 正义。 上海市药事所接到案源信息后，按规对涉案配送企业启动信用评价程序，要求配送企业指证失信行为的 实际控制主体。泓健医药公司提供了与河北常山生化药业公司关于涉案产品达肝素钠注射液的销售合 同、发票等信息，后续上海市药事所将对本案穿透至生产企业的河北常山生化药业公司启动信用评价。 2023年1月，当事人与上海泓健医药有限公司(以下简称"泓健医药公司")签订为期一年的《信息服务 ...

医药商业贿赂本质上是通过给予不正当利益影响处方权，干扰正常诊疗行为，妨碍公平竞争，加重医药 负担，使得医药产品销售从实际临床价值和产品的竞争力转为以高返点和高回扣驱动的不当竞争。司法 机关已经对行贿案件作出处罚，但案件暴露出的部分药品价格虚高空间依旧存在，虚高部分没有形成企 业正当盈利，也没有用于创新和质量，而是妨碍公平竞争。如不加以处置，虚高价格将持续侵害患者和 医保基金合法权益，也使合规经营企业受到错误示范。国家医保局于2020年建立价格招采信用评价制 度，对法院判决、有关部门查处的医药购销行贿、带金销售等问题突出的企业开展失信评级，并采取限 制挂网、配送等约束措施，使通过不当手段获取竞争优势的企业受相应约束，使合规经营企业感受公平 正义。 上海市药事所接到案源信息后，按规对涉案配送企业启动信用评价程序，要求配送企业指证失信行为的 实际控制主体。泓健医药公司提供了与河北常山生化药业公司关于涉案产品达肝素钠注射液的销售合 同、发票等信息，后续上海市药事所将对本案穿透至生产企业的河北常山生化药业公司启动信用评价。 来源："国家医保局"微信公号 2025年4月，上海市普陀区市场监督管理局在日常线索排查中发现上海 ...

Core Viewpoint - The Fujian Provincial Medical Security Bureau has announced the credit rating of two pharmaceutical companies, Beijing Kangrengtang Pharmaceutical Co., Ltd. and Guizhou Sanli Pharmaceutical Co., Ltd., both rated as "general" due to their involvement in commercial bribery cases [1][4]. Company Ratings - Beijing Kangrengtang Pharmaceutical Co., Ltd. was found to have engaged in bribery amounting to 46,000 yuan from 2013 to 2015 to medical institution personnel [2][4]. - Guizhou Sanli Pharmaceutical Co., Ltd. was involved in a bribery case where approximately 120,000 yuan was given to medical institution doctors to promote the prescription of its product, a children's throat spray [2][4]. Rating Criteria - The credit rating is based on the criteria set forth in the "Medical Price and Procurement Credit Rating Discretionary Standards" (2020 version), which states that companies involved in bribery exceeding 10,000 yuan but less than 150,000 yuan are rated as "general" [2][4].

Core Viewpoint - New Tian Pharmaceutical (002873) is embroiled in a bribery scandal, with allegations of bribing over 100 doctors across 37 medical institutions in Sichuan province, as reported in a notification from the Sichuan Provincial Health Commission [1][3][4]. Group 1: Allegations and Violations - The company is accused of multiple violations, including collecting false case data and conducting entertainment activities for doctors to promote its products [3][4]. - Allegations include the use of the Sunflower Alliance App to distribute survey projects to doctors, with an estimated bribe amount of approximately 72,600 yuan involving 55 doctors from 15 hospitals [3]. - The company reportedly organized 19 entertainment events for doctors in early 2025, involving 41 hospitals, to promote its products [3][4]. Group 2: Financial Performance - New Tian Pharmaceutical has experienced declining financial performance, with revenues of approximately 10.88 billion yuan, 9.54 billion yuan, and 8.58 billion yuan from 2022 to 2024, alongside net profits of 1.12 billion yuan, 810 million yuan, and 520 million yuan during the same period [9]. - The company’s sales expenses have been high, with sales expense rates exceeding 40% from 2022 to 2024, despite a downward trend in total sales expenses [6][9]. - In the first quarter of this year, the company reported a net profit decline of over 70%, with revenues of approximately 1.93 billion yuan, reflecting an 8.93% year-on-year increase [9]. Group 3: Industry Context - The pharmaceutical industry is facing challenges related to commercial bribery, often hidden within sales expenses, due to the high level of information asymmetry and reliance on doctors for product recommendations [7][8]. - Regulatory scrutiny is increasing, and if the allegations against New Tian Pharmaceutical are substantiated, it could lead to severe penalties and damage to the company's reputation [4][8].